$66.11
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,942 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.
Country

CH

CEO

Mr. David Endicott

IPO date

2019

Employees

25,942

ISIN

CH0432492467

Key stats

Open

$67.26

Volume

1.47M

Market cap

$26.61B

Prev. close

$67.90

Impl / hst vl

-

Open interest

$0.00

$65.20

Day’s Range

$67.33

$61.84

52W Range

$87.64

Valuation

44
Valuation score
Fairly Valued
P/E
45.41
P/S
3.50
P/B
1.68
Current ratio
2.20
Debt / Equity
0.17
ROE
3.71%
Gross margin
61.79%
Income growth
-12.90%
FCF growth
-50.33

May

7

Dividends

The last payment date was May 7, 2026

Div. per Share

$0.28

Div. Yield

0.41%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Buy

The average rating from top 11 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$99.77
The top 16 analysts forecasts that 12-month price may increase by 50.91%, with a low of $63.51 and a high of $125.46
$63.51
Low
$99.77
Avg
$125.46
High
Current price

Earnings

Q1 ‘26 revenue
$2.71B
Q1 ‘26 net income
$189.00M
Revenue
Net income
Previous EPS
$0.78
Estimate EPS
$0.82
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply